# Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers

> **NCT04782505** · PHASE1 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 61 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DWJ1248

## Key facts

- **NCT ID:** NCT04782505
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-12
- **Primary completion:** 2021-03-16
- **Final completion:** 2021-06-28
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04782505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04782505, "Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04782505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*